Aspen prescribes bolt-on acquisitions

Aspen Pharmacare is a R60bn pharmaceuticals giant that used to be a lot bigger. The share price is down over 57% in 5 years, reflecting an unsuccessful strategy to push into developed as well as emerging markets, all while steadily building up a debt pile. It’s a story that seems to play out over and over again: South African corporates …

View Post